Magnesium in Aneurysmal Subarachnoid Haemorrhage

A multi-centre, single blinded, randomised controlled trial of two target ranges for serum magnesium in patients with Subarachnoid Haemorrhage to reduce vasospasm

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12605000058673

Acronym

MASH Trial

Enrollment

162

Registered

2005-08-01

Start date

2010-01-01

Completion date

2010-01-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Patients had a reduced incidence of vasospasm but the resul was not significant. There was no difference between groupw

Interventions

Magnesium sulfate (20ml/hr). The concentration of magnesium will be titrated to the serum magnesium level in order to achieve a serum level of 1.6-2.5mmol/L, in the treatment group.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

<72 hours since haemorrhage

Exclusion criteria

1/Traumatic SAH. 2/Creatinine >0.2mmol/l. 3/Myasthenia Gravis. 4/Death imminent. 5/Vasospasm present on hospital admission.

Outcome results